Scientists infect older adults with RSV to unlock vaccine secrets
NCT ID NCT03728413
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how the immune system of older adults (ages 60-75) responds to a controlled infection with respiratory syncytial virus (RSV). Researchers gave 28 healthy volunteers a weakened form of the virus via nasal drops and monitored their symptoms and immune reactions for 14 days. The goal was to identify which parts of the immune response are most important for protection, which could guide the development of better RSV vaccines for the elderly.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- RSV A Memphis 37 (a weakened respiratory syncytial virus given as nasal drops)
- What this could lead to
- If successful, this study could reveal which immune targets are most important for protecting older adults against RSV, helping design better vaccines.
- What could go wrong
- This is a very small, early-stage study (28 participants) that deliberately infects people with a virus. It is not testing a treatment or vaccine, so direct benefits are unlikely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
28 people
The number who actually took part.
- Started
-
Nov 2018
- Finished
-
May 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy persons aged 60 to 75 years, able to give informed consent * Non smokers or ex-smokers with smokers with less than or equal to 5 pack years smoking history. * Spirometry within the normal range for age and height (+/- 15%) * FEV1/FVC \>70% pre-bronchodilator Exclusion Criteria: * Chronic respiratory disease (asthma, COPD, rhinitis, sinusitis) in adulthood * Inhaled bronchodilator or steroid use within the last 12 months * Habitual use of any medication or other product (prescription or over-the-counter) for symptoms of rhinitis or nasal congestion within the last 3 months * Acute upper respiratory infection (URI or sinusitis) in the past 6 weeks * Subjects with allergic symptoms present at baseline * Clinically relevant abnormality on chest X-ray * Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 3 years, other elderly adults (\>65 years), immunosuppressed persons, or those with chronic respiratory disease * Subjects with known or suspected immune deficiency * Receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months prior to challenge * Known IgA deficiency, immotile cilia syndrome, or Kartagener's syndrome * History of frequent nose bleeds * Any significant medical condition or prescribed drug deemed by the study doctor to make the participant unsuitable for the study * Women of childbearing potential must have a negative hCG urine pregnancy test \* * Positive urine drug screen * Women of childbearing potential will have a pregnancy test performed prior to virus inoculation to exclude pregnancy and be required to use contraception throughout the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Imperial College London
London, W12 0NN, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- How long does RSV protection last in a Baby's nose?
- Can a 5-Day pill tame RSV in the most vulnerable?
- Nasal spray vaccine aims to shield infants from RSV
- Could a simple pill tame RSV? new trial tests obeldesivir
- New swab test aims to spot COVID, flu, and RSV in minutes
- New device aims to detect flu, RSV, and COVID-19 in one quick test